Fujita K, Kubota T, Matsuzaki S W, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M
Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.
Anticancer Res. 1998 May-Jun;18(3B):1973-8.
The chemosensitivity test using the MTT endpoint is useful in predicting chemosensitivity.
One hundred twenty-eight patients with advanced gastric cancer were enrolled in the study, which mitomycin C (MMC), doxorubicin (DXR), 5-fluorouracil (5-FU), and cisplatin (DDP) were used.
The corresponding efficacy rates were 12.5% for MMC, 6.3% for DXR, 5.4% for 5-FU and 13.4% for DDP. The overall predictive accuracy was 78% in the patients with measurable lesions. Among the patients without measurable lesions, 21 were treated with a curative operation, and 33 with a non-curative operation. In those patients undergoing curative surgery, the "adapted" group detected by MTT assay survived longer than "non-adapted" cases (p < 0.05).
The present study provides further evidence that the chemosensitivity test may be useful for evaluating appropriate chemotherapy for advanced gastric cancer.
采用MTT终点法的化学敏感性试验在预测化学敏感性方面很有用。
128例晚期胃癌患者纳入本研究，使用了丝裂霉素C（MMC）、阿霉素（DXR）、5-氟尿嘧啶（5-FU）和顺铂（DDP）。
MMC的相应有效率为12.5%，DXR为6.3%，5-FU为5.4%，DDP为13.4%。在有可测量病灶的患者中，总体预测准确率为78%。在无可测量病灶的患者中，21例行根治性手术，33例行非根治性手术。在那些接受根治性手术的患者中，通过MTT试验检测出的“适应”组比“非适应”病例存活时间更长（p<0.05）。
本研究提供了进一步的证据，表明化学敏感性试验可能有助于评估晚期胃癌的合适化疗方案。
